These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35700552)

  • 1. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
    Fontrier AM
    Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
    Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
    Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe : Better access to medicines through HTA.
    Fontrier AM; Kamphuis B; Kanavos P
    Eur J Health Econ; 2024 Aug; 25(6):935-950. PubMed ID: 37917290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada.
    Mills M; Kanavos P
    Health Policy; 2022 Nov; 126(11):1130-1143. PubMed ID: 36050193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario?
    Fontrier AM; Kanavos P
    Value Health; 2023 Jul; 26(7):1011-1021. PubMed ID: 36889379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Market access to new anticancer medicines for children and adolescents with cancer in Europe.
    Schoot RA; Otth MA; Frederix GWJ; Leufkens HGM; Vassal G
    Eur J Cancer; 2022 Apr; 165():146-153. PubMed ID: 35235871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of the evolution in the access to orphan medicines in Spain].
    Mestre-Ferrándiz J; Iniesta M; Trapero-Bertran M; Espín J; Brosa M
    Gac Sanit; 2020; 34(2):141-149. PubMed ID: 31014554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influencing Factors of Health Technology Assessment to Orphan Drugs: Empirical Evidence in England, Scotland, Canada, and Australia.
    Zhou N; Ji H; Li Z; Hu J; Xie JH; Feng YH; Yuan N
    Front Public Health; 2022; 10():861067. PubMed ID: 35784205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases.
    Annemans L; Makady A
    Orphanet J Rare Dis; 2020 May; 15(1):127. PubMed ID: 32456653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of rarity in NICE's health technology appraisals.
    Clarke S; Ellis M; Brownrigg J
    Orphanet J Rare Dis; 2021 May; 16(1):218. PubMed ID: 33985575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HTA Barriers for Conditional Approval Drugs.
    Mills M
    Pharmacoeconomics; 2023 May; 41(5):529-545. PubMed ID: 36821044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries.
    Mills M; Michaeli D; Miracolo A; Kanavos P
    BMC Health Serv Res; 2023 Feb; 23(1):150. PubMed ID: 36782175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
    Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
    Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
    Nicod E; Annemans L; Bucsics A; Lee A; Upadhyaya S; Facey K
    Health Policy; 2019 Feb; 123(2):140-151. PubMed ID: 28400128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.